Transaction Details

Footnotes

On May 21, 2025, pursuant to the Agreement and Plan of Merger, dated as of February 6, 2025 and amended on April 21, 2025, by and among the Issuer, ACELYRIN, Inc. ("ACELYRIN"), and Arrow Merger Sub, Inc., a direct wholly owned subsidiary of the Issuer ("Merger Sub"), Merger Sub merged with and into ACELYRIN with ACELYRIN continuing as the surviving corporation and as a wholly owned subsidiary of the Issuer (the "Merger"). Each share of ACELYRIN common stock was exchanged for 0.4814 shares of the Issuer's common stock. | Received in exchange for 2,523,022 shares of common stock of ACELYRIN in connection with the Merger (as described in footnote 1) on May 21, 2025. | Shares are held directly by Samsara BioCapital, L.P. ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara GP") is the general partner of Samsara LP. The Reporting Person, as the managing member of Samsara GP, shares voting and investment authority over the shares held by Samsara LP. The Reporting Person disclaims beneficial ownership in these shares except to the extent of his pecuniary interest therein.